Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen Idec gets global rights to Knopp's ALS candidate; Deal terminated

Executive Summary

Knopp Neurosciences Inc. has licensed Biogen Idec Inc. exclusive worldwide rights to develop and commercialize Phase II KNS760704 (dexpramipexole) for amyotrophic lateral sclerosis and other indications.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register